Antibody-based biological antiviral drugs for the prevention and treatment of acute respiratory viral infections in immunocompromised patients: focus on safety
Geppe N.A. Zaplatnikov A.L. Kondyurina E.G. Blokhin B.M. Revyakina V.A. Kolosova N.G. Abdrakhmanova S.T. Romanova O.N.
24 October 2024Pharmarus Print Media
Russian Journal of Allergy
2024#21Issue 3368 - 381 pp.
The safety of drug therapy is of particular importance for immunocompromised patients. This aspect acquires high importance in the context of choosing tactics for the prevention and treatment of acute respiratory viral infections. The review presents data on the features of the antiviral immune response and common cold/influenza in patients with a burdened allergic history and a brief overview of the results of clinical studies on the effectiveness and safety of innovative biological antiviral drugs based on antibodies to biological targets. The drugs have a targeted effect on the immune system in accordance with their pharmacological targets, have a significant evidence base, including a meta-analysis of clinical trials for each drug according to the indication “acute respiratory viral infections/influenza”, as well as individual studies, including double-blind placebo-controlled randomized, with this pathology in immunocompromised patients. The article also includes the results of a generalized safety analysis of the use of the above drugs for the prevention and treatment of acute respiratory viral infections/influenza in patients with concomitant allergic and autoimmune pathology. The results of the conducted studies, meta-analyses and generalized statistical analysis of data on the use of the biological antiviral drugs based on antibodies for the prevention and treatment of acute respiratory viral infections/ influenza indicate proven efficacy and a favorable safety profile and allow us to recommend drugs for wide use with preventive and therapeutic purposes in accordance with indications, including patients with allergic and autoimmune pathology.
acute respiratory viral infection , allergies , antibodies , asthma , common cold , safety , treatment
Text of the article Перейти на текст статьи
The First Sechenov Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation
Novosibirsk State Medical University, Novosibirsk, Russian Federation
The Russian National Research Medical University named after N.I. Pirogov, Moscow, Russian Federation
Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russian Federation
Astana Medical University, Astana, Kazakhstan
Belarusian State Medical University, Minsk, Belarus
The First Sechenov Moscow State Medical University (Sechenov University)
Russian Medical Academy of Continuous Professional Education
Novosibirsk State Medical University
The Russian National Research Medical University named after N.I. Pirogov
Federal Research Center of Nutrition
Astana Medical University
Belarusian State Medical University
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026